Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.

Expert Comments:

"Sunesis Pharmaceuticals Inc. has been through a couple of life cycles now. It had a couple of programs in the early 2000s that didn't progress in the clinic, and so it reorganized, retooled and brought forward its Qinprezo (vosaroxin) compound in acute myeloid leukemia (AML). It got all the way through Phase 3 with its VALOR trial, and got negative topline results, unfortunately. I will give the company credit; it does have a path forward in Europe, where it has a shot at approval. . .Europeans are more flexible on their approval pathways, so this compound, if it gets approved in Europe, could help Sunesis bounce back from its current levels. . .the precedent for approval across the pond with a subset of Qinprezo data, censored for stem cell transplant in AML, does exist." read more >

Matthew Andrews, Wells Fargo Securities (7/31/15)
"While Sunesis Pharmaceuticals Inc. will discuss its potential options with its advisers in the coming weeks, a new Phase 3 study in early relapse/refractory patients 60 years or older (where Qinprezo's benefit appears most robust and clear) may ultimately be the company's best option to enable a future new drug application filing. . .Sunesis ended Q2/15 with $39.6M in cash (has roughly $19M available in its At The Market financing vehicle), which it believes is sufficient to fund operations to mid-2016."

David Nierengarten, Wedbush (7/30/15)
"Sunesis Pharmaceuticals Inc. ended Q2/15 with $39.6M in cash and cash equivalents, boosted by $18M in ATM common stock sales and option exercises. . .we are expecting approval in the European Union of vosaroxin in relapsed/refractory acute myeloid leukemia patients aged 60 years and older."

Mara Goldstein, Cantor Fitzgerald (7/30/15)
"Sunesis Pharmaceuticals Inc. proceeding with a filing in Europe represents some upside, in our view, as we think this is largely discounted by investors. . .the company has an early-stage pipeline that could produce first human data in late 2016 though limited attention has been paid to these compounds with Qinprezo being the overwhelming focus for investors. We believe these compounds have the ability to expand valuation for the shares."

Matthew Andrews, Wells Fargo Securities (7/24/15)
"We aren't surprised that the European commission's rapporteur/co-rapporteurs encouraged Sunesis Pharmaceuticals Inc. to proceed with a marketing authorization application (MAA) submission in relapsed/refractory acute myelogenous leukemia (AML) greater than 60 years, considering its flexibility with the Dacogen first-line elderly AML MAA, where at the initial Phase 3 overall survival analysis it was not statistically significant, and 2012 approval. Our base case has been that an MAA filing would proceed based on this regulatory precedent."

Hartaj Singh, BTIG Research (7/23/15)
"The European Medicines Agency meetings, independently with two different representatives, were positive in both instances, and Sunesis Pharmaceuticals Inc. will now focus on driving the European Union (EU) application forward. We assume a filing in Q4 EY/15, with a potential approval in late 2016; we still assume a 60% chance of EU approval."

Management Q&A: View From the Top
Daniel Swisher, Jr.
Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc., describes how his company is making clinical progress toward developing a new treatment for acute myelogenous leukemia, and how the broad Sunesis kinase inhibitor portfolio provides additional firepower against other cancers.
read more >

More Expert Comments

Experts Commenting on This Company

Matthew Andrews, Equity Senior Analyst – Wells Fargo Securities
Reni Benjamin, Senior Biotechnology Analyst – H.C. Wainwright & Co.
Mara Goldstein, Senior Analyst – Cantor Fitzgerald
David Nierengarten, Research Analyst – Wedbush
Joseph Pantginis, Senior Analyst – ROTH Capital Partners
Hartaj Singh, Biotechnology Analyst – BTIG Research
George Zavoico, Senior Equity Analyst – JonesTrading International Services LLC

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
Totality of VALOR data shows compelling risk-benefit trade-off in disease with significant unmet need
Relapsed/refractory AML is a significant commercial opportunity with no approved agents
Our kinase inhibitor pipeline is poised to progress to the clinic in 2015 and 2016
catalyst Calendar
Sunesis Pharmaceuticals Inc. Content